Get started
Author

Karolina Niewola‐Staszkowska

Observed names: K. Niewola, K. Niewola-Staszkowska, Karolina Niewola, Karolina Niewola-Staszkowska, Niewola-Staszkowska, Karolina
ORCID: 0000-0001-7225-3419
Observed ORCID: 0000-0001-7225-3419
OpenAlex ID: A5073306162
Decrease in plasma membrane tension triggers PtdIns(4,5)P2 phase separation to inactivate TORC2
2018 · Margot Riggi, Karolina Niewola-Staszkowska, et al. · Nature Cell Biology · 145
Dual action antifungal small molecule modulates multidrug efflux and TOR signaling
2016 · Tanvi Shekhar-Guturja, G M Kamal B Gunaherath, et al. · Nature Chemical Biology · 106
A Signaling Lipid Associated with Alzheimer’s Disease Promotes Mitochondrial Dysfunction
2016 · Michael A. Kennedy, Tia C. Moffat, et al. · Scientific Reports · 38
PDF
IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al. · Cancer Research Communications · 33
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
2023 · M.A. Deken, K. Niewola-Staszkowska, et al. · Immuno-Oncology Technology · 27
PDF
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
2024 · Claudia Kalla, German Ott, et al. · Translational Oncology · 9
A Neurotoxic Glycerophosphocholine Impacts PtdIns-4, 5-Bisphosphate and TORC2 Signaling by Altering Ceramide Biosynthesis in Yeast
2014 · Michael A. Kennedy, Kenneth Gable, et al. · PLoS Genetics · 7
PDF
Inhibition of autotaxin activity with IOA ‐289 decreases fibrosis in mouse E0771 breast tumors
2025 · Xiaoyun Tang, Humayara Khan, et al. · International Journal of Cancer · 3
IOA-289, a Novel, Clinical Stage Autotaxin Inhibitor for the Treatment of Fibrotic Lung Disease
2021 · M. Deken, K. Niewola-Staszkowska, et al. · American Journal of Respiratory and Critical Care Medicine · 3
PDF
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
2026 · Maciej Garczyk, Gonçalo Outeiro-Pinho, et al. · Cell Reports · 2
IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy
2026 · Evangelia Goulielmaki, Anna Tsapara, et al. · Cell Death Discovery · 2
PDF
922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models
2021 · Marcel Deken, Karolina Niewola, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion
2026 · Maciej Garczyk, Gonçalo Outeiro-Pinho, et al. · Cell Reports · 1
Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity
2022 · C. Tarantelli, F. Spriano, et al. · European Journal of Cancer · 1
PDF
131P Translating a novel autotaxin inhibitor from preclinical proof of concept in pancreatic cancer to a biomarker response in human subjects
2021 · S. Milleri, M. Deken, et al. · Annals of Oncology · 1
Abstract 1877: IOA-237 - A potent anti-CD73 mAb demonstrates monotherapeutic and combination efficacy in solid tumor models
2021 · Marcel A. Deken, Alan M. Carruthers, et al. · Cancer Research · 1
Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion.
2026 · Garczyk, Maciej, Outeiro-Pinho, Gonçalo, et al. · Open Access CRIS of the University of Bern
33 (PB021): Loss-of-function and gain-of-function genetic screens identify potential biomarkers and combination partners for the highly selective allosteric PI3Kδ inhibitor roginolisib (IOA-244)
2024 · C. Tarantelli, G. Sartori, et al. · European Journal of Cancer
Abstract B165: A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3Kδ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models
2023 · Chiara Tarantelli, Elisa Civanelli, et al. · Molecular Cancer Therapeutics
A novel orally available type IV autotaxin inhibitor, IOA-289, ameliorates steatosis and fibrosis in a preclinical model of non-alcoholic steatohepatitis
2023 · Marit ten Hove, Giusy Di Conza, et al. · Journal of Hepatology
Table S1 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al.
Figure S4 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al.
PDF
Table S2 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al.
Figure S3 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al.
Figure S3 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
2023 · Zoë Johnson, Chiara Tarantelli, et al.
PDF
Works count: 48
Citation count: 381
H-index: 7
I10-index: 5
Year
Topic
Type